Damon Race/LinkedIn
Jun 25, 2026, 15:28
Damon Race: Pursuing Long-Term Expression in Hemophilia A Gene Therapy
Damon Race, President and CEO of GeneVentiv Therapeutics, Inc., shared a post on LinkedIn:
“Met up with my friends from ReciPharm Advanced Bio at BIO International 2026.
ReciPharm is a wonderful partner in our efforts to advance GENV-HEM, the first gene therapy with durable expression biology for patients with hemophilia A with or without inhibitors.
A special thank you to Greg Behar and Jhomar Marquez.”
Stay updated with Hemostasis Today.
-
Sep 20, 2026, 11:27Edward Lee Carter: Prasugrel Dosing Matters in P2Y12 Inhibitor Comparisons After PCI
-
Sep 20, 2026, 09:51Ceasovschih Alexandr: A Closer Look at Lipid Disorders in CKM Syndrome
-
Sep 20, 2026, 09:05World Stroke Academy: Can Adjunct IAT Improve Tissue Reperfusion?
-
Sep 20, 2026, 06:46Neeraj Songara: From Donated Blood to Engineered Therapeutics
-
Sep 20, 2026, 06:24Louise St. Germain Bannon: Improving Awareness and Care for Women Across the Lifespan
-
Sep 20, 2026, 05:17Maxime Dely: When ABO Compatibility Isn’t Enough for Safe Transfusion
-
Sep 20, 2026, 04:54William Aird: What Does a Complete History and Physical Really Mean?
-
Sep 20, 2026, 04:34Hons Saurabh Kaushik: Why Uncontrolled LDL Can Be Harmful
-
Sep 20, 2026, 03:58Salih Ehsan: The Complexities of HbF and HbA2